DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20180673

Cost variation analysis of different brands of commonly prescribed antihypertensive drugs, available in Indian market: a pharmacoeconomic study

Shakeel Ahmad Mir

Abstract


Background: Worldwide, Hypertension is estimated to cause 7.5 million deaths, about 12.8% of the total of all deaths. This accounts for 57 million disability adjusted life years (DALYS) or 3.7% of total DALYS. Globally, the overall prevalence of hypertension in adults aged 25 and over was around 40% in 2008.Despite its benefits, treatment of hypertension is costly. Direct medical spending to treat hypertension totalled $42.9 billion in 2010, with almost half ($20.4 billion) in the form of prescription medications. Being, a silent disease, adherence to antihypertensive drugs is poor. One of the important factors of poor adherence to antihypertensives is the cost of the drugs. There is wide cost variation among different brands of the same antihypertensive drug. Clinician’s awareness of cost of therapeutics is poor. The costly brand of same generic drug is proved to be in no way superior to its economically cheaper counterpart.

Methods: The minimum and the maximum cost in Rupees (INR) of a particular antihypertensive agent manufactured by various pharmaceutical companies in the same strength were noted. The cost of 10 tablets/capsules was calculated. The cost ratio and percent cost variation were calculated for each brand.

Results: The cost variation observed in the present study was as high as 2337.50 % for Hydralazine. Other significantly high cost variations found in the present study were: 1315.25% (Telmisartan+Hydrochlorthiazide), 870.58% (Amlopdipine), 558.34% (Amlodipine+Atenolol), 537.68% (Valsartan), 394.44% (Metoprolol), 344.44% (Enalapril), 316.22% (Propranolol), 300% (Lisinopril), 290.90% (Carvedilol), 289% (Cilnidipine), 271.99% ( Labetolol), 268.04% (Indapamide), 256.31% (Losartan), 255.19% (Irbesartan), 226% (Methyldopa), 223.04% (Frusemide), 209.78% (Nitrendepine), 192.08% (Terazosin), 189.25% (Atenolol), 142.42% (Bisoprolol) and 120.51% (Felodipine).

Conclusions: Financial constraints are a reality in almost all aspects of medicine. Doctors must consider drug costs to their patients. Increasing pharmaceutical costs negatively impacts patients. Given the increasing healthcare costs, there is growing interest in rational prescribing, which takes costs of medication into account.


Keywords


Antihypertensives, Adherence, Branded drugs, Cost analysis, Hypertension

Full Text:

PDF

References


REFERENCES

Health Action International (HAI). Drug Pricing and Access to Essential Medicines.2007. Available at: http://trade.ec.europa.eu/doclib/docs/2005/april/tradoc_122213.pdf accessed on 09.01.2018.

World Health organization (WHO). Public Education in Rational Drug Use: a global survey. Available at: http://apps.who.int/medicinedocs/pdf/s2235e/s2235e.pdf

Management Sciences for Health (MSH). Evaluating the cost of pharmaceuticals. 2007. Available at: http://www.who.int/medicines/technical_briefing/tbs/06-TG_Evaluating-drug-costs_final-08.pdf. Accessed 09.01.2018.

Piette JD, Heisler M, Wagner TH. Cost-related medication underuse among chronically ill adults: The treatments people forgo, how often, and who is at risk. Am J Public Health. 2004;94:1782-7.

William J. Elliott. The Economic Impact of Hypertension J Clin Hypertens. 2003;5(3,2):3-13.

Kardas P, Bishai WR. Compliance in infective medicine. Adv Stud Med. 2006;6(7C):S652-8.

Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336:1114-7.

Mir SA. A calm look at the cost of various brands of antiasthmatic drugs available in India. Int J Basic Clin Pharmacol. 2016;5:142-5.

Gupta RK, Reddy PS. A calm look on cost analysis of different brands of anti-epileptic drug. J MGIMS. 2011;16(i):64-6.

Andayani TM, Imaningsih I. Cost analysis of antidiabetic drugs for diabetes mellitus out patient in Kodya Yogyakarta hospital. Malay J pharm Sci. 2007;5(1):19-23.

Nathan RR, Steven DV. Cost Analysis of Glaucoma medication. Am J Ophthalmol. 2008;145:106-13.

Akila L, Rani RJ. Cost analysis of different brands of antianginal drugs available in India. Int J Basic Clin Pharmacol. 2015;4:860-3.

Mir SA. Cost analysis of different brands of antimicrobial agents available in India. Int J Basic Clin Pharmacol. 2016;5:85-9.

Marie TB, Jennifer KB. Medication Adherence: WHO Cares? Mayo Clin Proc. 2011;86(4):304-14.

Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: A systematic review. PLoS Med. 2007;4(9):e283.

Burnier M. Drug Adherence in Hypertension. In: Jagadeesh G, Balakumar P, Maung UK. (eds) Pathophysiology and Pharmacotherapy of Cardiovascular Disease. Adis, Cham; 2015.

Ananthakrishnan G. A historic move to make drugs affordable. The Hindu, India; 2016. Available at: http://www.thehindu.com/opinion/op-ed/a-historic-move-to-make-drugs-affordable/article2991869.ece. accessed on 09.01.2018

Umamaheswari A, Prabu SL, Puratchikody A. Drug Affordability in India - an Analytical Review. MOJ Bioequiv. 2017;3(6):00053.

Lowy DR, Low L, Warner RS. A survey of physician’s awareness of drug costs. Am J Edu. 1972;47:349-55.